{'fraction_non_alphanumeric': 0.04864864864864865, 'fraction_numerical': 0.03423423423423423, 'mean_word_length': 4.786458333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MicroRNA‑34a/c function as tumor suppressors in Hep‑2 laryngeal carcinoma cells and may reduce GALNT7 expression.

A family of small non-coding RNAs, ~22 nt in length, known as microRNAs (miRNAs), regulating ~30% of all human gene expression, have been reported to be involved in the pathogenesis of a number of types of cancers, including laryngeal squamous cell carcinoma (LSCC). In the current study, miR-34a and miR-34c were observed to be downregulated in human LSCC tissues. Ectopic expression of miR-34a and miR-34c in Hep-2 cells significantly induced the cell proliferation and migration ability in vitro. UDP-N-acetyl-α-D-galactosamine:polypeptide-N-acetylgalactosaminyltransferase 7 (GALNT7), whose expression is negatively regulated by miR-34a and miR-34c in Hep-2 cells, is conﬁrmed to be a novel direct target gene of miR-34a and miR-34c. In conclusion, the current results suggest that miR-34a and miR-34c may function as tumor suppressors in LSCC through downregulation of GALNT7. The study of miR-34a, miR-34c and its novel target, GALNT7, may serve as novel potential makers for LSCC therapy.